GSKCONS.NS - GlaxoSmithKline Consumer Healthcare Limited

NSE - NSE Delayed Price. Currency in INR
6,641.40
+15.75 (+0.24%)
At close: 3:29PM IST
Stock chart is not supported by your current browser
Previous Close6,625.65
Open6,620.00
Bid6,641.40 x 0
Ask0.00 x 0
Day's Range6,540.00 - 6,720.00
52 Week Range4,851.00 - 6,720.00
Volume12,242
Avg. Volume12,669
Market Cap277.886B
BetaN/A
PE Ratio (TTM)43.85
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GSK CEO: Our top priority is to invest in growth in our c...
    CNBC Videos13 days ago

    GSK CEO: Our top priority is to invest in growth in our c...

    Emma Walmsley, GlaxoSmithKlein CEO, speaks to CNBC's Meg Tirrell at the J.P. Morgan Health Care Conference about reshaping the company and her outlook for 2018.

  • GSK's history spans three centuries and started in three ...
    CNBC Videoslast month

    GSK's history spans three centuries and started in three ...

    GSK has roots in the UK, US and New Zealand. 300 years later, mergers and acquisitions has made it the healthcare and pharmaceutical company it is today.

  • Reuters12 days ago

    GSK CEO says looking at Pfizer consumer business, but not a priority

    Pfizer, the largest U.S. drugmaker, said last year it was considering strategic alternatives, including a sale or spinoff, of the consumer business, which had sales of about $3.4 billion in 2016 and could cost more than $15 billion to acquire. "At this stage it would be weird if we didn't look at it," GSK Chief Executive Emma Walmsley said, responding to questions at the JP Morgan Healthcare Conference in San Francisco. Despite her consumer products background, Walmsley repeatedly said that the company's pharmaceuticals business and pharma research and development is GSK's top priority.

  • Reuters12 days ago

    GSK CEO says looking at Pfizer consumer business, but not a priority

    Pfizer, the largest U.S. drugmaker, said last year it was considering strategic alternatives, including a sale or spinoff, of the consumer business, which had sales of about $3.4 billion in 2016 and could cost more than $15 billion to acquire. "At this stage it would be weird if we didn't look at it," GSK Chief Executive Emma Walmsley said, responding to questions at the JP Morgan Healthcare Conference in San Francisco. Despite her consumer products background, Walmsley repeatedly said that the company's pharmaceuticals business and pharma research and development is GSK's top priority.

  • Glaxo Shifts Gears to Fire Up Growth With Rival Astra Closing In
    Bloomberg12 days ago

    Glaxo Shifts Gears to Fire Up Growth With Rival Astra Closing In

    CEO Walmsley has reshuffled 40 percent of top managers to spark innovation

  • What Should We Expect From GlaxoSmithKline plc’s (LON:GSK) Earnings In The Years Ahead?
    Simply Wall St.12 days ago

    What Should We Expect From GlaxoSmithKline plc’s (LON:GSK) Earnings In The Years Ahead?

    GlaxoSmithKline plc’s (LSE:GSK) latest earnings update in September 2017 confirmed that the company faced a immense headwind with earnings falling by -89.17%. Below, I’ve laid out key growth figures onRead More...

  • The Wall Street Journal12 days ago

    Rivals Help Fund Regeneron’s Gene-Sequencing Effort

    Some of the world’s largest pharmaceutical companies are pooling resources to fund an ambitious genetic and medical database aimed at bolstering the search for new drugs.

  • Glaxo CEO Replaced 50 Top Managers in Shakeup to Spur Growth
    Bloomberg12 days ago

    Glaxo CEO Replaced 50 Top Managers in Shakeup to Spur Growth

    GlaxoSmithKline Plc’s new chief executive officer, Emma Walmsley, has revamped the top ranks of the U.K.’s largest drugmaker, replacing about 50 of the top 125 managers since taking over last year.

  • 1 Reason Dynavax Technologies Corporation Stock Soared in 2017
    Motley Fool13 days ago

    1 Reason Dynavax Technologies Corporation Stock Soared in 2017

    Thanks to the FDA approval of its hepatitis B vaccine, Dynavax's shares crushed the broader market in 2017.

  • Spark, Glaxo Gene Therapies Near $1 Million — Still A Bargain?
    Investor's Business Daily18 days ago

    Spark, Glaxo Gene Therapies Near $1 Million — Still A Bargain?

    Spark and GlaxoSmithKline are pricing the world's first approved gene therapies at prices approaching $1 million.

  • U.K. Clears Glaxo's $700,000 ‘Bubble Boy Disease’ Gene Therapy
    Bloomberg18 days ago

    U.K. Clears Glaxo's $700,000 ‘Bubble Boy Disease’ Gene Therapy

    The U.K.’s thrifty health authority has cleared its most expensive medicine ever -- a $700,000 GlaxoSmithKline Plc treatment for an illness known as “bubble-boy disease.” But the overall cost to the country’s ...

  • 3 Top Dividend Stocks With Yields Over 4%
    Motley Fool21 days ago

    3 Top Dividend Stocks With Yields Over 4%

    High-yield stocks have gotten harder to find in the current bull market, but these three should please even the pickiest income investors.

  • Benzinga21 days ago

    Barron's Picks And Pans: Chevron, Corning, GlaxoSmithKline And More

    This weekend's Barron's examines why things may be looking up for one big oil company. Other featured articles offer the prospects for a big drug maker facing stiff competition and a glassmaker that may ...

  • Barrons.com22 days ago

    [$$] Glaxo: Expect a Speedy Recovery

    Advair, the world’s top-selling respiratory drug, will probably face generic competition in the U.S. beginning in 2018. It’s the biggest moneymaker for United Kingdom-based GlaxoSmithKline , whose earnings estimates have been sliding, and whose shares have tumbled since the summer. To see why, look back to Pfizer (PFE) seven years ago, on the eve of Lipitor’s patent expiration.

  • GuruFocus.com24 days ago

    GlaxoSmithKline Is a Massive Bargain

    Wide moat and low price equals deep discounts for investors

  • Market Realist26 days ago

    Measuring Sanofi’s Valuation This December

    For 3Q17, Sanofi reported revenues of 9.05 billion euros—a 4.7% YoY (year-over-year) rise in operating revenues, compared with 9.03 billion in 3Q16.

  • Should You Sell GlaxoSmithKline plc (LON:GSK) At This PE Ratio?
    Simply Wall St.27 days ago

    Should You Sell GlaxoSmithKline plc (LON:GSK) At This PE Ratio?

    GlaxoSmithKline plc (LSE:GSK) is trading with a trailing P/E of 27.2x, which is higher than the industry average of 25.7x. While GSK might seem like a stock to avoid orRead More...

  • Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb
    Motley Foollast month

    Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb

    Which stock wins in a head-to-head match-up between these two big drugmakers?

  • 3 High-Yield Stocks Still Worth Buying
    Motley Foollast month

    3 High-Yield Stocks Still Worth Buying

    All three companies pay at least double the average yield of the S&P 500.

  • Reuterslast month

    GlaxoSmithKline boosts stake in Saudi Arabia unit

    British drugmaker GlaxoSmithKline (GSK.L) (GSK) said on Monday it has boosted its stake in its Saudi Arabian unit to 75 percent as it seeks to benefit from the kingdom's plan to transform the economy and raise local manufacturing of pharmaceutical products. Before the acquisition, GSK owned 49 percent of Glaxo Saudi Arabia, a business it formed in 1992 with local partner Banaja KSA Holding Company. "The acquisition represents a step forward towards the strengthening of our operations in the kingdom," said Andrew Miles, vice president and general manager of GSK in the Gulf Cooperation Council states.

  • GuruFocus.comlast month

    Stocks That Fell to 3-Year Lows in the Week of Dec. 15

    General Electric Co. (GE), GlaxoSmithKline PLC (GSK), Ferrellgas Partners LP (FGP) and Crescent Point Energy Corp. (CPG) have declined to their respective three-year lows.

  • 10 Biggest Antidepressant Drug Companies In 2017
    Insider Monkeylast month

    10 Biggest Antidepressant Drug Companies In 2017

    The 10 biggest antidepressant drug companies in 2017 are committed to providing the safest and most cost-effective solution for consumers suffering from mental diseases worldwide. According to Journal of the American Medical Association, one out of six Americans consumes psychiatric medicine and about 12% of these drugs are antidepressants. Depression is a state of mind, […]

  • Benzingalast month

    ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More

    The curtains have come down on one of the most-watched annual biotech conferences. The 59th annual meeting of the American Society of Hematology was held Dec. 9-12 in Atlanta.  This year's meeting was ...

  • Glaxo's Nucala Label Expansion Application Gets FDA Approval
    Zackslast month

    Glaxo's Nucala Label Expansion Application Gets FDA Approval

    GlaxoSmithKline's (GSK) application to include treatment of eosinophilic granulomatosis with polyangiitis in Nucala's label was approved by the FDA.

  • Glaxo's New Pharma Head Looks to Move Fast, Especially in Cancer
    Bloomberglast month

    Glaxo's New Pharma Head Looks to Move Fast, Especially in Cancer

    GlaxoSmithKline Plc, the U.K.’s biggest drugmaker, signaled it will look to speed development of an experimental cancer treatment as part of its ambition to expand in oncology just two years after selling ...